AUS
NZ
UK
CA
USA
IND
Healthcare
Immuron Reports Strong Sales Growth for Travelan® Across Global Markets
January 17, 2025 11:30 AM AEDT| By Team Kalkine MediaHighlights,Global Sales Surge:,Travelan® global sales reached AUD $2.5 million in the December 2024 Quarter, up 70% from the prior quarter and 249% compared to the same period in 2023.,Australian Market Leads Growth:,Australian sales increased 90% qu...
Telix maintains steady growth, while Pro Medicus secures another contract.
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaTelix maintains steady growth, while Pro Medicus secures another contract.
Phase III Trials: A Critical Moment for These ASX Health Stocks
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaMajor ASX Biotechs Make Significant Advances in Phase III Trials
How Is Singular Health Group Transforming Medical Imaging Efficiency?
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Singular Health Group (ASX:SHG) completes Phase 1 of its MOU with Provider Network Solutions, showcasing technical proof of concept.,The company’s proprietary 3Dicom Gateway and Medical File Transfer Protocol reduce medical image processi...
Will Recce Pharmaceuticals' R327G Gel Redefine Infection Treatment?
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Second phase trial completed with no serious adverse events reported,R327G gel developed for bacterial skin and skin structure infections,Third phase clinical studies planned in the United States, Australia, and Indonesia,Recce Pharmaceuti...
Dimerix Launches Key Paediatric Study in Groundbreaking Phase 3 Clinical Trial
January 16, 2025 08:57 PM AEDT| By Team Kalkine MediaHighlights,Recruitment begins for the first paediatric patient in a pivotal kidney disease trial.,19 specialist sites across multiple countries involved in the paediatric study plan.,Interim data anticipated in August; full recruitment expected by la...
Pro Medicus Signs $33M Deal with University of Kentucky
January 16, 2025 05:19 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (ASX:PME) secures a long-term contract valued at $33 million.,Visage 7 Enterprise Imaging Platform to be implemented at University of Kentucky.,Company’s North American market expansion continues with strategic partnerships.,Me...
Pro Medicus (ASX:PME) Secures $33 Million Deal to Modernize Imaging Systems at the University of Kentucky
January 16, 2025 05:06 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (ASX:PME) signs a significant $33 million contract with the University of Kentucky.,Visage 7 cloud platform to replace outdated imaging systems across the university.,The 9-year agreement accelerates Pro Medicus’ North American...
Chemist Warehouse Merger with Sigma Healthcare to Reshape the ASX 200
January 16, 2025 03:20 PM AEDT| By Team Kalkine MediaHighlights,Sigma Healthcare (ASX:SIG) and Chemist Warehouse merger set to bring substantial index weight changes.,Analysts anticipate $537 million in trades from index trackers.,Passive fund flows likely to impact other ASX 200 members.,Sigma Healthc...
Memphasys’ Antioxidant Profiling System Gains Recognition in Prestigious Publication
January 16, 2025 11:20 AM AEDT| By Team Kalkine MediaHighlights:,Memphasys,Ltd (,ASX:MEM,) has received recognition for its proprietary,RoXsta,antioxidant profiling system through a key scientific publication.,The publication in the journal,Antioxidants,highlights,RoXsta's,ability to profile oxidative...
Innovative Deals Drive Progress in HealthTech & Pharmaceuticals
January 16, 2025 11:00 AM AEDT| By Team Kalkine MediaInnovative Deals Drive Progress in HealthTech & Pharmaceuticals
PYC Therapeutics (ASX:PYC) Investors Face AU$68 Million Loss
January 15, 2025 09:33 PM AEDT| By Team Kalkine MediaHighlights:,PYC Therapeutics (ASX:PYC) showcases diverse ownership with significant individual and insider stakes. -,Institutional investors hold a smaller fraction, suggesting growth potential. -,Private companies and the general public contribute t...
Neuren Faces Market Challenges Amid European Progress
January 15, 2025 11:46 AM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals (NEU) sees stock decline despite EU progress.,Acadia Pharmaceuticals (ACAD) applies for Rett syndrome treatment approval in Europe.,Significant stock depreciation,noted,over the past year.,Shares of Neuren Pharmaceut...
Biotechnology Partnership Seeks to Expand Rett Syndrome Drug into European Market
January 15, 2025 11:00 AM AEDT| By Team Kalkine MediaBiotechnology Partnership Seeks to Expand Rett Syndrome Drug into European Market
Could Aroa Biosurgery Transform Soft Tissue Regeneration?
January 15, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Dr. Adam Young's expertise enriches the advanced soft tissue regeneration technology at Aroa Biosurgery (ASX:ARX).,A distinct scientific methodology drives innovations in soft tissue repair.,The technology offers versatility across diverse...
Will US Health Policy Changes Impact Australian Biotech Firms?
January 15, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Robert F. Kennedy Jr. assumes the health secretary role amid policy uncertainties affecting Australian biotech firms in the US.,Companies such as CSL Limited (ASX:CSL), Cochlear Limited (ASX:COH), ResMed Inc. (ASX:RMD), and Fisher & Payke...
Atomo Diagnostics Secures Long-Term Supply Agreement with Newfoundland Diagnostics
January 14, 2025 12:28 PM AEDT| By Team Kalkine MediaHighlights,New Agreement,: Atomo Diagnostics enters a new five-year supply agreement with Newfoundland Diagnostics, worth approximately,AU$5.44 million,.,Exclusive Distribution Rights,: The agreement grants Newfoundland exclusive rights to distribute...
Nanosonics (ASX: NAN) Appoints Gerard Dalbosco to the Board to Strengthen Global Strategy in Healthcare
January 14, 2025 12:26 PM AEDT| By Team Kalkine MediaHighlights,Gerard,Dalbosco,joins,Nanosonics,(NAN) board.,Dalbosco,brings significant,expertise,in finance, M&A, and strategy.,Nanosonics,continues to strengthen its healthcare sector position.,In an exciting development, Nanosonics (ASX:NAN), a leade...
Telix Pharmaceuticals Shares Surge 7% After Outperforming FY24 Guidance
January 14, 2025 11:45 AM AEDT| By Team Kalkine MediaHighlights,Telix Pharmaceuticals shares rise 7% to AU$25.79 following a strong FY24 performance update.,Fourth-quarter unaudited revenue increased 46% year-on-year to US$142 million (AU$218 million), driving full-year revenue up 55% to US$517 million...
Mesoblast Secures $260m to Power Cell Therapy Growth
January 14, 2025 11:38 AM AEDT| By Team Kalkine MediaHighlights,Mesoblast (MSB) completes a $260 million capital raise.,Funds to support,Ryoncil's,US launch and manufacturing expansion.,Shares dipped by 6.4% following the announcement.,Mesoblast Limited (ASX:MSB) has successfully raised $260 million th...
Advertise your brand on Kalkine Media